348 related articles for article (PubMed ID: 7509000)
1. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.
Richman DD; Havlir D; Corbeil J; Looney D; Ignacio C; Spector SA; Sullivan J; Cheeseman S; Barringer K; Pauletti D
J Virol; 1994 Mar; 68(3):1660-6. PubMed ID: 7509000
[TBL] [Abstract][Full Text] [Related]
2. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates.
Nájera I; Richman DD; Olivares I; Rojas JM; Peinado MA; Perucho M; Nájera R; López-Galíndez C
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1479-88. PubMed ID: 7534096
[TBL] [Abstract][Full Text] [Related]
3. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Tisdale M; Kemp SD; Parry NR; Larder BA
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
[TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
Larder BA; Kohli A; Bloor S; Kemp SD; Harrigan PR; Schooley RT; Lange JM; Pennington KN; St Clair MH
J Virol; 1996 Sep; 70(9):5922-9. PubMed ID: 8709213
[TBL] [Abstract][Full Text] [Related]
5. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.
Iversen AK; Shafer RW; Wehrly K; Winters MA; Mullins JI; Chesebro B; Merigan TC
J Virol; 1996 Feb; 70(2):1086-90. PubMed ID: 8551567
[TBL] [Abstract][Full Text] [Related]
6. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
[TBL] [Abstract][Full Text] [Related]
7. 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors.
Larder BA
Antimicrob Agents Chemother; 1992 Dec; 36(12):2664-9. PubMed ID: 1282792
[TBL] [Abstract][Full Text] [Related]
8. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
Larder BA; Kellam P; Kemp SD
Nature; 1993 Sep; 365(6445):451-3. PubMed ID: 7692302
[TBL] [Abstract][Full Text] [Related]
9. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
Larder BA; Kemp SD; Harrigan PR
Science; 1995 Aug; 269(5224):696-9. PubMed ID: 7542804
[TBL] [Abstract][Full Text] [Related]
10. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
Loya S; Bakhanashvili M; Tal R; Hughes SH; Boyer PL; Hizi A
AIDS Res Hum Retroviruses; 1994 Aug; 10(8):939-46. PubMed ID: 7529032
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor.
Staszewski S; Massari FE; Kober A; Göhler R; Durr S; Anderson KW; Schneider CL; Waterbury JA; Bakshi KK; Taylor VI
J Infect Dis; 1995 May; 171(5):1159-65. PubMed ID: 7538547
[TBL] [Abstract][Full Text] [Related]
12. Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment.
Di Stefano M; Sabri F; Leitner T; Svennerholm B; Hagberg L; Norkrans G; Chiodi F
J Clin Microbiol; 1995 Feb; 33(2):352-5. PubMed ID: 7536214
[TBL] [Abstract][Full Text] [Related]
13. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group.
Imrie A; Beveridge A; Genn W; Vizzard J; Cooper DA
J Infect Dis; 1997 Jun; 175(6):1502-6. PubMed ID: 9180194
[TBL] [Abstract][Full Text] [Related]
14. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity.
de Jong MD; Loewenthal M; Boucher CA; van der Ende I; Hall D; Schipper P; Imrie A; Weigel HM; Kauffmann RH; Koster R
J Infect Dis; 1994 Jun; 169(6):1346-50. PubMed ID: 8195615
[TBL] [Abstract][Full Text] [Related]
15. Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase.
Kleim JP; Bender R; Kirsch R; Meichsner C; Paessens A; Riess G
Virology; 1994 May; 200(2):696-701. PubMed ID: 7513921
[TBL] [Abstract][Full Text] [Related]
16. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.
Richman D; Shih CK; Lowy I; Rose J; Prodanovich P; Goff S; Griffin J
Proc Natl Acad Sci U S A; 1991 Dec; 88(24):11241-5. PubMed ID: 1722324
[TBL] [Abstract][Full Text] [Related]
17. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.
Balzarini J; Karlsson A; Pérez-Pérez MJ; Camarasa MJ; Tarpley WG; De Clercq E
J Virol; 1993 Sep; 67(9):5353-9. PubMed ID: 7688822
[TBL] [Abstract][Full Text] [Related]
18. Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase.
Buckheit RW; Fliakas-Boltz V; Yeagy-Bargo S; Weislow O; Mayers DL; Boyer PL; Hughes SH; Pan BC; Chu SH; Bader JP
Virology; 1995 Jun; 210(1):186-93. PubMed ID: 7540784
[TBL] [Abstract][Full Text] [Related]
19. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team.
Shafer RW; Iversen AK; Winters MA; Aguiniga E; Katzenstein DA; Merigan TC
J Infect Dis; 1995 Jul; 172(1):70-8. PubMed ID: 7541064
[TBL] [Abstract][Full Text] [Related]
20. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.
Harrigan PR; Kinghorn I; Bloor S; Kemp SD; Nájera I; Kohli A; Larder BA
J Virol; 1996 Sep; 70(9):5930-4. PubMed ID: 8709214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
